|Articles|September 22, 2022

New Phesi Analysis of Alzheimer’s Patients Highlights Need for Preventative Approach that Includes Younger Participants

Analysis of 117,000 patients reveals rapid rate of decline in Alzheimer’s patients with 18% loss in cognitive function over a 12-month period.

Phesi identified 117,463 patients who participated in disease modifying trials; representing a significant portion of the patient population. The Phesi analysis reveals the decline that occurs in Alzheimer’s patients over a single 12-month period, with the average 72-year-old suffering from Alzheimer’s losing 18% of cognitive function (measured by MMSE) in 12 months.

Read more about the analysis here.


Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content